Related Experiment Video
Updated: May 6, 2026

Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
MALToma Discovered on a Hemorrhagic Shock Associated with Gastric Dieulafoy's Lesion: A Case Report
Elina Lam1, Raoul Muteganya2, Nathalie Nagy3
1Department of Gastro-Enterology, Hôpital Universitaire de Bruxelles (HUB), Bruxelles, Belgium.
Introduction:
Dieulafoy's lesion is a rare but severe cause of digestive bleeding and can rarely present as a hemorrhagic shock which is associated with a severe prognosis. MALToma is a B-cell lymphoma of the mucosa-associated lymphoid tissue. It was reported that MALToma can be revealed by a Dieulafoy's lesion. Due to the lack of specific endoscopic or clinical characteristics, several endoscopies may be needed to establish the diagnosis of MALToma.
Case Presentation:
A 61-year-old male patient presented to the emergency department with melena and hematemesis. The patient was transferred to the intensive care unit due to hemorrhagic shock. The endoscopic work-up showed large gastric folds which were later confirmed as MALToma in anatomo-pathologic analysis. The echoendoscopy showed a vessel going through the entire gastric wall which endoscopically corresponded to a red non-bleeding lesion, confirming Dieulafoy's lesion as the origin of the bleeding. The patient received an endoscopic treatment and was rapidly discharged from the intensive care unit. The evolution was spontaneously favorable, and there was no repeat active bleeding.
Conclusion:
A gastric MALToma was discovered thanks to a hemorrhagic shock on a Dieulafoy's lesion which has not yet been described in the literature.
Related Concept Videos
What is Monogastric Digestion?
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

